FUJIREBIO-EUROPE
23.6.2022 09:41:07 CEST | Business Wire | Press release
H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx NeuroSciences NV today announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros. Pending the satisfaction of customary closing conditions, the deal is expected to close in July 2022. ADx NeuroSciences becomes a wholly owned subsidiary of Fujirebio Europe NV.
“ By welcoming ADx NeuroSciences in the Fujirebio group of companies, Fujirebio will be able to expand its antibody supply business and contract development and manufacturing (CDMO) offerings in the neurodegenerative field to our partners globally,” says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “Fujirebio is committed to invest in developing diagnostic kits in the field of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. We are excited to work together with the ADx NeuroSciences team to expand the global neurodegeneration biomarker testing market.”
“It is a unique opportunity for us to completely integrate the CDMO-based open platform strategy of Fujirebio in this way,” states Koen Dewaele, CEO of ADx NeuroSciences. “Our partners will benefit from the synergies between our teams and the speed with which we can bring our antibodies and assays to the diagnostics industry and on various platforms, all under the high-quality mark of excellence for which Fujirebio has become well known.”
ADx NeuroSciences specializes in generating tailor-made antibodies and developing assays for pharma and in vitro diagnostics (IVD) companies. As part of Fujirebio, ADx NeuroSciences will continue to serve its current partners and customers in their diagnostic biomarker development and will continue to expand its extensive portfolio of state-of-the-art biomarkers and antibodies to help detect neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Its current pipeline encompasses, next to several phospho-tau specific antibodies for measurement in plasma, biomarkers targeting synaptic degeneration supporting prognosis of these devastating diseases.
Fujirebio is a trusted partner for high-quality IVD testing solutions and a historical pioneer in neurodegenerative disease diagnostics. The company will combine the unique know-how and biomarker portfolio of ADx NeuroSciences with both its own solid experience in bringing high quality IVD products to the market and its strategic CDMO partnerships that make unique testing solutions available to the entire diagnostics industry. The acquisition also concentrates considerable additional know-how, expertise, and resources in the Fujirebio Neuro Center of Excellence.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., whose name represents “Healthcare for you” and which is a listed company on Tokyo Stock Exchange (TSE: 4544), is a global leader in the field of high-quality IVD testing. Founded in 1950, it has more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products. With Fujirebio Holdings Inc., located in Tokyo, Japan, its subsidiaries are located in Japan, US and Europe.
Fujirebio was the first company to develop and market CSF biomarkers for Alzheimer’s disease testing, under the Innogenetics brand, over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools.
About ADx NeuroSciences
ADx NeuroSciences is an R&D driven company specialized in the development of neurodegenerative biomarkers. Its expertise is used by pharmaceutical and diagnostic companies for the conception, development, production, and worldwide commercialization of novel biomarkers.
ADx NeuroSciences was founded in 2011 and is now working with the top pharmaceutical and diagnostic companies in US, Europe, Japan, and China. These collaborations result in new diagnostic assays that support the development of promising drugs either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays are used in neurodegenerative diseases like Alzheimer’s disease and Parkinson’s and can be applied to a variety of platforms for research up to IVD use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005429/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JSS: 2025 Sake Exports Grew Steadily, Reaching a Record 81 Markets6.2.2026 04:00:00 CET | Press release
Sake exports continued to expand in 2025 in both value and volume, with export destinations reaching a record 81 countries and regions. Export value increased 6% year on year to 45.9 billion yen, while export volume rose 8% to 33.55 million liters (3.73 million cases on a 9-liter basis), marking the second-highest export performance on record. The average export unit price per 750 ml bottle declined 2% year on year to 1,026 yen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205671686/en/ Sake Export Performance by Country (Top 10, 2025) Export value has nearly doubled since 2020, and the CAGR over the past five years reached 14%. This underscores sake’s position as a high-growth category globally. Asia remained the largest export destination, with export value totaling 28.8 billion yen, representing an 8% increase year on year and accounting for 63% of total export value. North America recorded exports of 12.4 billion ye
Canva Brings On-Brand Designs Directly into AI Assistants6.2.2026 00:00:00 CET | Press release
Designs created in ChatGPT now come to life in Canva, instantly on brand and ready to use The future of work is being rewritten by AI, with professionals accomplishing in minutes what used to take hours. But there's been one persistent breaking point in AI assistants: generic visual outputs and off-brand colors that undermine AI speed with tedious manual cleanup. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205384226/en/ Canva Today, that friction ends as Canva brings brand intelligence directly into the AI tools where modern day work happens most. Starting now, ChatGPT users can create designs completely tied to their Canva Brand Kit, making a company’s brand come to life visually and function as a living participant in AI workflows. This expansion marks the coming together of Canva and ChatGPT, two category-defining platforms, in a new way to make on-brand design more accessible and fluid. From client-ready pitch deck
DNIB.com Reports Internet Has 386.9 Million Domain Name Registrations at the End of the Fourth Quarter of 20255.2.2026 23:04:00 CET | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the fourth quarter of 2025 closed with 386.9 million domain name registrations across all top-level domains (TLDs), an increase of 8.4 million domain name registrations, or 2.2% compared to the third quarter of 2025. Domain name registrations also increased by 22.7 million, or 6.2%, year over year. The .com and .net TLDs had a combined total of 173.5 million domain name registrations in the domain name base at the end of the fourth quarter of 2025, an increase of 1.6 million domain name registrations, or 0.9% compared to the third quarter of 2025. The .com and .net TLDs had a combined increase of 4.5 million domain name registrations, or 2.6%, year over year. As of Dec. 31, 2025, the .com domain name base totaled 161.0 million domain name registrations and the .net
Calix CEO Michael Weening To Keynote at MWC26 Barcelona: How Agentic AI Enables an ‘Experience of One’ for Every Subscriber5.2.2026 20:30:00 CET | Press release
In a livestreamed keynote at Mobile World Congress, Weening will reveal how service providers can turn agentic AI into operational advantage, personalizing at scale to grow subscribers while increasing ARPU and reducing churn Calix, Inc. (NYSE: CALX) today announced that President and Chief Executive Officer Michael Weening will deliver a keynote in the Tuesday morning, March 3, “Architects of the AI Age” session at MWC26 Barcelona. Calix’s presence at MWC, the world’s largest and most influential connectivity event, extends the momentum following the recent launch of the company’s AI‑native platform. Weening will take the MWC Main Stage on Tuesday morning to reveal a transformative vision for telecommunications: how agentic AI enables service providers to deliver an “experience of one” to millions of subscribers simultaneously—personalizing every interaction in real time, unlocking new revenue streams, and fundamentally redefining what it means to grow in the connected world. He will
Andersen Consulting udvider sine kompetencer med tilføjelsen af SHMA5.2.2026 19:20:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med SHMA, en førende virksomhed inden for aktuarfaglig og finansiel rådgivning med hovedsæde i De Forenede Arabiske Emirater. SHMA er et aktuarfagligt rådgivningsfirma med næsten fire årtiers erfaring i at hjælpe organisationer med at navigere i kompleksitet, håndtere risiko og skabe muligheder gennem aktuarfaglig og forsikringsmæssig rådgivning, risikostyring samt værdiansættelse af slutvederlag (End-of-Service Benefits, EOSB). Ved at samarbejde med forsikringsselskaber, pensionsordninger samt private og offentlige organisationer hjælper SHMA sine kunder med at opbygge robuste og resiliente organisationer. "Hos SHMA er kvalitet, skræddersyede løsninger og ægte menneskelig forbindelse i centrum for vores mission," udtaler Shariq Sikander, direktør for SHMA. "Samarbejdet med Andersen Consulting giver os mulighed for at udvide vores indflydelse globalt og styrke vores aktuarfaglige ydelser ud over MENA-regionen, samtidig med at vi leverer in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom